|
Q1 FY2027
As of Jul 31, 2026
|
Q4 FY2026
As of Apr 30, 2026
|
Q3 FY2026
As of Jan 31, 2026
|
Q2 FY2026
As of Oct 31, 2025
|
Q1 FY2026
As of Jul 31, 2025
|
Q4 FY2025
As of Apr 30, 2025
|
Q3 FY2025
As of Jan 31, 2025
|
Q2 FY2025
As of Oct 31, 2024
|
Q1 FY2025
As of Jul 31, 2024
|
Q4 FY2024
As of Apr 30, 2024
|
Q3 FY2024
As of Jan 31, 2024
|
Q2 FY2024
As of Oct 31, 2023
|
Q1 FY2024
As of Jul 31, 2023
|
Q4 FY2023
As of Apr 30, 2023
|
Q3 FY2023
As of Jan 31, 2023
|
Q2 FY2023
As of Oct 31, 2022
|
Q1 FY2023
As of Jul 31, 2022
|
Q4 FY2022
As of Apr 30, 2022
|
Q3 FY2022
As of Jan 31, 2022
|
Q2 FY2022
As of Oct 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current Assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Receivables, less allowance; $667; $633, on each respective date | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Property, plant and equipment, at cost | ||||||||||||||||||||
| Accumulated depreciation | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Right of use assets | ||||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||||
| Net Book Value | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Liabilities and Stockholders' Equity | ||||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||||
| Short-term borrowings | ||||||||||||||||||||
| Current portion of financing liability | ||||||||||||||||||||
| Current portion of term loans | ||||||||||||||||||||
| Current portion of financing lease liabilities | ||||||||||||||||||||
| Current portion of operating lease liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Employee compensation and amounts withheld | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Other accrued expenses | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Long-term portion of financing liability | ||||||||||||||||||||
| Long-term portion of seller notes | ||||||||||||||||||||
| Long-term portion of term loans | ||||||||||||||||||||
| Long-term portion of financing lease liabilities | ||||||||||||||||||||
| Long-term portion of operating lease liabilities | ||||||||||||||||||||
| Accrued pension and deferred compensation costs | ||||||||||||||||||||
| Deferred income taxes | ||||||||||||||||||||
| Other non-current liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders' Equity: | ||||||||||||||||||||
| Common stock, $2.50 par value, Authorized – 5,000 shares; Issued – 3,012 shares; 2,969 shares; Outstanding – 2,895 shares; 2,866 shares, on each respective date | ||||||||||||||||||||
| Additional paid-in-capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Common stock in treasury, at cost, 117 shares; 103 shares, on each respective date | ||||||||||||||||||||
| Total Kewaunee Scientific Corporation Stockholders' Equity | ||||||||||||||||||||
| Non-controlling interest | ||||||||||||||||||||
| Total Stockholders' Equity | ||||||||||||||||||||
| Total Liabilities and Stockholders' Equity | ||||||||||||||||||||
| Treasury stock, shares (in shares) | ||||||||||||||||||||
Loading...
